ASCO 2022 Conference Coverage


 

ASCO 2022 on Randomized Phase II Trial of Neoadjuvant ADT + Abiraterone & Apalutamide for High-Risk Localized Prostate Cancer: Pathologic Response and PSMA Imaging Correlates

254 views
June 9, 2022
Comments 0
Login to view comments. Click here to Login